# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001493152-24-040286
Filing Date
2024-10-07
Accepted
2024-10-07 16:15:21
Documents
6
Period of Report
2024-10-07

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | formdef14a.htm | DEF 14A | 622939
2 |  | formdef14a_001.jpg | GRAPHIC | 70020
3 |  | formdef14a_002.jpg | GRAPHIC | 56354
4 |  | formdef14a_003.jpg | GRAPHIC | 237725
5 |  | proxycard_001.jpg | GRAPHIC | 3062168
6 |  | proxycard_002.jpg | GRAPHIC | 1759345
| Complete submission text file | 0001493152-24-040286.txt |  | 7748990

Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-11460 | Film No.: 241358027
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)